reactions. In 453 of the reports, tramadol was the sole suspected drug. These reactions suggest that the decision to prescribe tramadol should be carefully considered.
Like codeine, tramadol is metabolised via the CYP2D6 isoenzyme of cytochrome P450 to an active metabolite which binds to µ receptors. Patients who metabolise drugs poorly via CYP2D6 (about 7% of Caucasians) may get less benefit from tramadol (and codeine) due to reduced formation of the active metabolite. Tramadol is also metabolised by CYP3A4 so its activity is reduced by drugs which induce CYP3A4. 3 The analgesic effects of tramadol are not completely reversed by the opioid antagonist naloxone and some patients who do not respond to codeine do respond to tramadol. This suggests that tramadol has additional mechanisms of action. Tramadol inhibits reuptake of serotonin and noradrenaline and this probably contributes to its analgesic effects.
There is no doubt that tramadol is an effective analgesic for moderate, and in some cases, severe pain. 4 In comparative studies in postoperative and post-trauma pain, tramadol 100 mg intramuscularly or intravenously was equivalent to 5-10 mg of morphine. However, in severe pain associated with either surgery or cancer, morphine was more effective than tramadol and remains the drug of choice. In acute and chronic non-malignant pain, oral tramadol 100 mg is comparable to a combination of paracetamol and codeine (1000 mg/60 mg). There have been few direct comparisons of tramadol with non-steroidal anti-inflammatory drugs, but efficacy appears to be similar.
When choosing between equally effective analgesics, relative safety is important. In the case of tramadol, adverse effects are common and sometimes serious. Tramadol binds weakly to opioid receptors, so at normal doses constipation and respiratory depression occur less frequently than with opioids.
However, these effects can, and do, occur at higher doses.
Tramadol is metabolised in the liver and excreted by the kidneys, so doses should be adjusted in patients with impaired liver or kidney function, and in the elderly. 5 Other opioid-like effects occur commonly at normal doses, including nausea, vomiting, dizziness and confusion. Titrating the dose slowly may improve tolerability, but this may be impractical in acute pain. A major problem is dizziness which can contribute to falls in at-risk patients. Dizziness appears in 13% of the reports received by ADRAC. In some cases the mechanism of interaction is unclear. For example, tramadol may increase the effects of warfarin. 5 The patient's INR should therefore be carefully monitored.
The potential for abuse and dependence with tramadol is low. Increased quantities and repeats for both tramadol sustainedrelease tablets, and codeine phosphate with paracetamol will only be granted if the doctor obtains approval from the HIC for such an authority, which is generally limited to one month's therapy. Authorities for increased maximum quantities and/or repeats will be granted only for severe disabling pain not responding to non-narcotic analgesics.
